Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H18ClNO.ClH |
| Molecular Weight | 324.245 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1CCC2=CC(Cl)=C(O)C=C2[C@H](C1)C3=CC=CC=C3
InChI
InChIKey=OYCAEWMSOPMASE-XFULWGLBSA-N
InChI=1S/C17H18ClNO.ClH/c1-19-8-7-13-9-16(18)17(20)10-14(13)15(11-19)12-5-3-2-4-6-12;/h2-6,9-10,15,20H,7-8,11H2,1H3;1H/t15-;/m1./s1
SCH-23390 is a potent and selective antagonist of the dopamine-1 and dopamine-5 receptors (Ki = 0.2 and 0.3 nM respectively). It was found to prevent death from d-amphetamine overdose in rats and has also been investigated as a potential treatment for Parkinson's Disease and Bipolar Disorder. A single clinical trial was conducted in healthy humans where SCH-23390 induced akathisia (motor restlessness). Preclinical and clinical trials as therapeutic have been discontinued due to side-effects and lack of efficacy. However, it should be noted that a C11 radiolabeled version of the compound has been synthesized and used as a PET imaging probe for the study of Parkinson's Disease and Huntington's Disease.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P21728 Gene ID: 1812.0 Gene Symbol: DRD1 Target Organism: Homo sapiens (Human) |
0.2 nM [Ki] | ||
Target ID: P21918 Gene ID: 1816.0 Gene Symbol: DRD5 Target Organism: Homo sapiens (Human) |
0.3 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats. | 1991 |
|
| Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice. | 1991 |
|
| D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats. | 1992 |
|
| Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice. | 1999 Aug |
|
| Macrophage Fcgamma receptors expression is altered by treatment with dopaminergic drugs. | 1999 Mar |
|
| D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. | 1999 Mar 10 |
|
| Halogenated boldine derivatives with enhanced monoamine receptor selectivity. | 2000 Apr |
|
| Spatiotemporal analysis of Fos expression associated with cocaine- and PTZ-induced seizures in prenatally cocaine-treated rats. | 2001 Jul |
|
| Involvement of serotonergic and dopaminergic mechanisms in hyperthermia induced by a serotonin-releasing drug, p-chloroamphetamine in mice. | 2001 Nov 2 |
|
| Characterization of the distribution of the cocaine priming threshold and the effect of SCH23390. | 2002 Aug 16 |
|
| Combined intrastriatal dopamine D1 and serotonin 5-HT2 receptor stimulation reveals a mechanism for hyperlocomotion in 6-hydroxydopamine-lesioned rats. | 2003 |
|
| A 68930 and dihydrexidine inhibit locomotor activity and d-amphetamine-induced hyperactivity in rats: a role of inhibitory dopamine D(1/5) receptors in the prefrontal cortex? | 2004 |
|
| The transcription factor NGFI-B (Nur77) and retinoids play a critical role in acute neuroleptic-induced extrapyramidal effect and striatal neuropeptide gene expression. | 2004 Feb |
|
| Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. | 2005 Aug |
|
| Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. | 2005 Dec 15 |
|
| The role of tissue plasminogen activator in methamphetamine-related reward and sensitization. | 2005 Feb |
|
| Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. | 2005 Mar |
|
| Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists. | 2005 Oct |
|
| Histamine H3 receptor agonist- and antagonist-evoked vacuous chewing movements in 6-OHDA-lesioned rats occurs in an absence of change in microdialysate dopamine levels. | 2006 Dec 15 |
|
| Influence of nitric oxide on morphine-induced amnesia and interactions with dopaminergic receptor agents. | 2006 Jun 15 |
|
| Delayed L-DOPA-induced hyperalgesia. | 2006 Nov |
|
| Pharmacological studies of the opioids, mood stabilizer and dopaminergic drugs on pilocarpine-induced seizures and status epilepticus. | 2006 Nov 13 |
|
| Cocaine increases endoplasmic reticulum stress protein expression in striatal neurons. | 2007 Mar 16 |
|
| Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. | 2007 Oct 1 |
|
| Effects of dopamine and NMDA receptors on cocaine-induced Fos expression in the striatum of Fischer rats. | 2008 Dec 3 |
|
| Dopamine neurotransmission is involved in the attenuating effects of 5-HT3 receptor antagonist MDL 72222 on acute methamphetamine-induced locomotor hyperactivity in mice. | 2008 Jan |
|
| Role of dopamine D1-like receptors in methamphetamine locomotor responses of D2 receptor knockout mice. | 2008 Jul |
|
| Transient D1 dopamine receptor expression on prefrontal cortex projection neurons: relationship to enhanced motivational salience of drug cues in adolescence. | 2008 Mar 5 |
|
| Effect of cocaine on Fas-associated protein with death domain in the rat brain: individual differences in a model of differential vulnerability to drug abuse. | 2009 Apr |
Sample Use Guides
SCH-23390 was tested in four healthy subjects at doses of 310–810 micrograms delivered intravenously. SCH-23390 induced akathisia at the three highest doses.
Route of Administration:
Intravenous
Rat brain striatal slices were preincubated with [3H]GABA and superfused in the presence of the GABA transport inhibitor nipecotic and GABA aminotransferase inhibitor aminooxyacetic acids. GABA efflux was estimated by monitoring the efflux of [3H]GABA. The overflow of GABA evoked by electrical field stimulation was blocked by 0.5 - 10 microM of SCH 23390.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
11957535
Created by
admin on Sat Dec 16 04:55:39 GMT 2023 , Edited by admin on Sat Dec 16 04:55:39 GMT 2023
|
PRIMARY | |||
|
4S8T3E2F4Z
Created by
admin on Sat Dec 16 04:55:39 GMT 2023 , Edited by admin on Sat Dec 16 04:55:39 GMT 2023
|
PRIMARY | |||
|
125941-87-9
Created by
admin on Sat Dec 16 04:55:39 GMT 2023 , Edited by admin on Sat Dec 16 04:55:39 GMT 2023
|
PRIMARY | |||
|
DTXSID9074484
Created by
admin on Sat Dec 16 04:55:39 GMT 2023 , Edited by admin on Sat Dec 16 04:55:39 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
